Home
News
Create
Screeners
Insights
Ishita Drugs & Indus
80.
71
-0.19
(-0.23%)
Market Cap
₹24.14 Cr
PE Ratio
27.24
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.23%
1M
+10.55%
6M
+9.07%
1Y
+2.13%
5Y
+144.58%
View Company Insights
Latest news about Ishita Drugs & Indus
Ishita Drugs & Industries Ltd Confirms Non-Applicability of SEBI Regulation 32(1) for FY26
Apr 13, 2026
Ishita Drugs & Industries Ltd notified BSE Limited that SEBI Regulation 32(1) regarding statement of deviation from proceeds is not applicable for FY26 ended 31st March, 2026. The company confirmed it did not raise funds through public issue, rights issue, preferential issue, or QIP during this period. The communication was signed by Managing Director Jagdish Agrawal and submitted on 13th April, 2026.
Ishita Drugs and Industries Limited Submits SEBI Compliance Certificate for Q4FY26
Apr 10, 2026
Ishita Drugs & Industries: Related Party Makes Second Share Acquisition
Feb 27, 2026
Ishita Drugs and Industries Limited Files SEBI Disclosure for Substantial Acquisition
Feb 14, 2026
Ishita Drugs Q3FY26 Results: Revenue Falls 24% to ₹313.62 Lakhs
Feb 07, 2026
More news about Ishita Drugs & Indus
30
Jan 26
Ishita Drugs & Industries Ltd Schedules Board Meeting on February 07, 2026 for Q3FY26 Financial Results
Ishita Drugs & Industries Ltd has scheduled a board meeting for February 07, 2026, to approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025. The meeting complies with SEBI Regulation 29 requirements. A trading window closure is in effect from January 1, 2026, until 48 hours after results announcement, following insider trading prevention protocols.
31
Dec 25
Ishita Drugs & Industries Promoter Jagdish Agrawal Acquires Additional 254 Shares
Jagdish Agrawal, promoter of Ishita Drugs & Industries Ltd, acquired 254 equity shares worth ₹2,540 through open market transactions on December 29, 2025. His shareholding increased marginally from 4.40% to 4.41%, with total holding rising from 131,555 to 131,809 shares. The acquisition was disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations. The company's equity share capital remains stable at ₹2.99 crores comprising 2,990,300 shares of ₹10 each.
10
Dec 25
Ishita Pharmaceuticals Increases Stake in Ishita Drugs & Industries to 1.02%
Ishita Pharmaceuticals has increased its stake in Ishita Drugs & Industries to 1.02% through an additional acquisition of 560 shares worth Rs. 10.00 each on December 08, 2025. This follows earlier investments, bringing the total holding to 30,550 shares from the previous 29,990 shares, representing continued strategic interest between the related pharmaceutical companies.
11
Nov 25
Ishita Drugs & Industries Reports Mixed Q2 Results, Progresses on Facility Upgrade
Ishita Drugs & Industries Limited reported Q2 FY2026 revenue of Rs. 806.81 lakhs, up from Rs. 692.92 lakhs in Q1. However, net profit declined to Rs. 14.33 lakhs from Rs. 30.23 lakhs. The company is upgrading its manufacturing facility to comply with Revised Schedule M regulations, with Rs. 50 lakhs spent on civil construction. The project faced delays due to extended monsoon. The company maintains a strong liquidity position with Rs. 472.68 lakhs in cash and bank balances.
Ishita Drugs & Indus
80.
71
-
0.
19
(-
0.
23
%)
1 Year Returns:
+2.13%
Industry Peers
Sun Pharmaceutical
1,620.40
(-
3.
55
%)
Divis Laboratories
6,361.50
(-
0.
27
%)
Torrent Pharmaceuticals
4,117.20
(-
0.
72
%)
Dr Reddys Laboratories
1,317.10
(-
1.
04
%)
Lupin
2,296.10
(-
1.
93
%)
Cipla
1,295.00
(-
0.
83
%)
Mankind Pharma
2,267.40
(-
1.
11
%)
Zydus Life Science
927.40
(-
2.
00
%)
Aurobindo Pharma
1,413.80
(-
1.
50
%)
Glenmark Pharmaceuticals
2,299.50
(-
1.
52
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO